๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

โœ Scribed by M. Ychou; J. Raoul; F. Desseigne; C. Borel; F. Caroli-Bosc; J. Jacob; J. Seitz; A. Kramar; A. Hua; P. Lefebvre; C. Couteau; Y. Merrouche

Publisher
Springer
Year
2002
Tongue
English
Weight
279 KB
Volume
50
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Updated efficacy and toxicity analysis o
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : Intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
โœ Amanda C. Ashley; Daniel J. Sargent; Steven R. Alberts; Axel Grothey; Megan E. C ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 163 KB

## Abstract ## BACKGROUND. Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofiโ€Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741. ## METHODS. This IROX regimen was oxaliplatin 85 mg/m^2^ and irinotecan 200

Randomized multicenter Phase II trial of
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma
โœ Emilio Bajetta; Maria Di Bartolomeo; Luigi Mariani; Antonio Cassata; Salvatore A ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 124 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as firstโ€line treatment in metastatic colorectal carcinoma (CRC). ## METHODS A total of 140 patients received capecitabine at a dose of 1